Trial Profile
A Retrospective study of Olaparib in patient with HER2-negative metastatic breast cancer with Germline BRCA mutation or Lesional BRCA mutation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jun 2018
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 13 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology